No abstract

The immune-mediated tissue destruction of graft- vs -host disease (GvHD) remains a major barrier to greater use of hematopoietic stem cell transplantation (HSCT). Mesenchymal stem cells (MSCs) have intrinsic immunosuppressive qualities and are being actively investigated as a therapeutic strategy for treating GvHD. We characterized Cymerus™ MSCs, which are derived from adult, induced pluripotent stem cells (iPSCs), and show they display surface markers and tri-lineage differentiation consistent with MSCs isolated from bone marrow (BM). Administering iPSC-MSCs altered phosphorylation and cellular localization of the T cell-specific kinase, Protein Kinase C theta (PKCθ), attenuated disease severity, and prolonged survival in a humanized mouse model of GvHD. Finally, we sevaluated a constellation of pro-inflammatory molecules on circulating PBMCs that correlated closely with disease progression and which may serve as biomarkers to monitor therapeutic response. Altogether, our data suggest Cymerus iPSC-MSCs offer the potential for an off-the-shelf, cell-based therapy to treat GvHD.

No abstract

No abstract

ABSTRACT. Total IgG concentrations, IgG antibody concentrations to pooled Escherichia coli antigens, and IgG anti-E. coli antibody avidity were measured in cord and maternal serum samples collected from 52 mother-infant pairs after premature delivery (mean gestational age 28 wk, range 23-33 wk). The mean IgG anti-E. coli antibody concentration in cord serum (1.86 relative units/mL) was markedly lower than in maternal serum . These findings suggest that there is selective transplacental transport of high avidity antibody with enhanced opsonic activity for these antigens early in the 3rd trimester of pregnancy. (Pediatr Res 27: 365-371, 1990)